Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (NASDAQ: BIIB) generates frequent news across neurology, rare diseases and immunology, reflecting its role as a biotechnology company focused on serious neurological and genetic conditions. News coverage for BIIB often centers on clinical trial results, regulatory milestones, scientific publications and strategic collaborations that shape the company’s therapeutic portfolio.
Investors and healthcare observers following Biogen news can expect updates on marketed therapies such as SPINRAZA (nusinersen) for 5q spinal muscular atrophy, QALSODY (tofersen) for SOD1-ALS, and LEQEMBI (lecanemab-irmb) for early Alzheimer’s disease, co-developed with Eisai. Recent announcements have included European Commission approval of a high-dose SPINRAZA regimen, long-term QALSODY data published in JAMA Neurology, and multiple LEQEMBI data presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, including subcutaneous administration and long-term treatment analyses.
Biogen news also highlights its collaborations and pipeline. Examples include joint updates with Stoke Therapeutics on zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome, and a research collaboration with Dayra Therapeutics to discover oral macrocyclic peptides for immunological conditions. In addition, the company regularly issues press releases on scientific conference presentations, regulatory submissions, and its broader ALS and Alzheimer’s research programs.
This BIIB news page aggregates such developments in one place, helping readers track Biogen’s clinical progress, regulatory interactions and research directions over time. For investors, clinicians and researchers, it offers a focused view of how Biogen’s scientific and business activities evolve across its key therapeutic areas.
Sage Therapeutics and Biogen announced that their CORAL Study achieved both primary and secondary endpoints in treating major depressive disorder (MDD) with zuranolone 50 mg. The trial demonstrated a statistically significant reduction in depressive symptoms at Day 3 and over a 2-week period compared to placebo. Participants reported adverse effects mostly mild or moderate, with no new safety signals. The results suggest zuranolone may accelerate the efficacy of existing antidepressants. A conference call will discuss the findings further.
Biogen and Xbrane Biopharma AB have entered a commercialization agreement to develop Xcimzane™, a proposed biosimilar referencing CIMZIA®, indicated for conditions such as rheumatoid arthritis and psoriasis. CIMZIA® generated €1.8 billion in 2020 sales. Biogen will handle global rights and make an upfront payment of $8 million to Xbrane, with potential milestones reaching $80 million. This collaboration aims to increase patient access to affordable treatments while bolstering Biogen's biosimilar pipeline.
Biogen has opted to participate in the development of mosunetuzumab, a bispecific antibody for treating B-cell non-Hodgkin’s lymphoma, by paying a $30 million option fee to Genentech. This investigational therapy targets CD20 and CD3, having received Breakthrough Therapy Designation from the FDA for adult patients with relapsed/refractory follicular lymphoma. Biogen will share in the operating profits in the low to mid 30% range and is eligible for royalties outside the U.S. Additionally, mosunetuzumab is in trials for systemic lupus erythematosus.
Biogen (Nasdaq: BIIB) announces the retirement of Board members Nancy Leaming and Brian Posner, effective at the 2022 annual meeting. Leaming, with a background in healthcare insurance, and Posner, a private investor, have served on the Board since 2008. Their contributions have been vital in guiding Biogen's mission in developing therapies for neurological diseases. The leadership expressed gratitude for their service, emphasizing the company's ongoing commitment to innovation in neuroscience and addressing climate health issues.
Biogen Inc. (Nasdaq: BIIB) has finalized a deal with Samsung Biologics for the sale of its equity stake in the Samsung Bioepis joint venture for up to $2.3 billion. This includes an immediate cash payment of $1 billion and deferred payments totaling $1.25 billion over two years. Biogen will maintain commercial rights for certain biosimilars, including BYOOVIZ and an investigational candidate, SB15. This move is viewed as a significant step in continuing Biogen's portfolio and enhancing financial flexibility.
Biogen and Eisai announced details of the ENVISION Phase 4 study of ADUHELM for early Alzheimer’s disease, aiming for 1,500 participants, inclusive of 18% from Black/African American and Latinx backgrounds. This initiative emphasizes diversity in clinical trials, essential for relevant data. The study's primary endpoint will assess cognitive function after 18 months, utilizing CDR-SB. While the trial progresses, Biogen faces potential Medicare coverage restrictions for ADUHELM. The patient screening is set to begin in May 2022.
Biogen has exercised its option to obtain a worldwide, exclusive license for BIIB115, a preclinical investigational antisense oligonucleotide aimed at treating spinal muscular atrophy (SMA). This includes a $60 million upfront payment to Ionis Pharmaceuticals. BIIB115 is intended to address unmet needs in SMA treatment and has potential for extended dosing intervals. Biogen will handle all development costs, including future milestone payments and royalties on net sales. BIIB115 may significantly enhance treatment options for SMA patients.
Biogen and Ionis Pharmaceuticals announced a strategic collaboration whereby Biogen exercised its option to acquire a worldwide, exclusive license to develop and commercialize BIIB115/ION306, an investigational antisense oligonucleotide targeting spinal muscular atrophy (SMA). This initiative aims to address unmet patient needs and is supported by a $60 million upfront payment from Biogen. Plans include advancing BIIB115 into clinical trials to evaluate its safety and efficacy, with Biogen handling all development costs.
On December 23, 2021, Eisai and Biogen announced that their investigational Alzheimer's treatment, lecanemab, received Fast Track designation from the U.S. FDA. This designation aims to expedite development for drugs addressing serious conditions. Lecanemab has previously been granted Breakthrough Therapy designation in June 2021. The ongoing Phase 3 Clarity AD study includes 1,795 patients, with results expected to confirm clinical benefits. Lecanemab targets amyloid-beta aggregates, showing promise in reducing clinical decline based on Phase 2 results.
Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced that Japan's First Committee on New Drugs (NDC) will continue deliberations on the application for aducanumab, aimed at treating Alzheimer’s disease. The NDC has requested additional data for the manufacturing and marketing approval process. Both companies are committed to collaborating with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to meet these requirements. Aducanumab, a monoclonal antibody, targets amyloid beta in Alzheimer’s patients.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
